These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 32717614)
1. The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors. Raubo P; Evans R; Willis P Bioorg Med Chem Lett; 2020 Sep; 30(18):127412. PubMed ID: 32717614 [TBL] [Abstract][Full Text] [Related]
2. The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial. Patel NR; Cunoosamy DM; Fagerås M; Taib Z; Asimus S; Hegelund-Myrbäck T; Lundin S; Pardali K; Kurian N; Ersdal E; Kristensson C; Korsback K; Palmér R; Brown MN; Greenaway S; Siew L; Clarke GW; Rennard SI; Make BJ; Wise RA; Jansson P Int J Chron Obstruct Pulmon Dis; 2018; 13():1009-1019. PubMed ID: 29628759 [TBL] [Abstract][Full Text] [Related]
3. The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. Brown DS; Cumming JG; Bethel P; Finlayson J; Gerhardt S; Nash I; Pauptit RA; Pike KG; Reid A; Snelson W; Swallow S; Thompson C Bioorg Med Chem Lett; 2012 Jun; 22(12):3879-83. PubMed ID: 22608965 [TBL] [Abstract][Full Text] [Related]
4. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451 [TBL] [Abstract][Full Text] [Related]